Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys.
Antibody seroprevalence
COVID-19
Herd immunity
Oman
Prevalence
SARS-CoV-2
Sero-epidemiological surveys
Serosurvey
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
14
08
2021
revised:
24
09
2021
accepted:
24
09
2021
pubmed:
4
10
2021
medline:
15
12
2021
entrez:
3
10
2021
Statut:
ppublish
Résumé
To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors. In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8-6.2%) in Cycle 1 to 22% (19.6-24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6-10.9%) vs 3.2% (2.6-3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0-27.9%) vs 16.8% (14.9-18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64-2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04-2.35). This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity.
Identifiants
pubmed: 34601146
pii: S1201-9712(21)00770-0
doi: 10.1016/j.ijid.2021.09.062
pmc: PMC8482550
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
269-277Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement None declared.
Références
Int J Epidemiol. 2021 Aug 30;50(4):1077-1090
pubmed: 33893483
Lancet Reg Health Am. 2021 Sep;1:100018
pubmed: 35013735
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Lancet Glob Health. 2021 May;9(5):e598-e609
pubmed: 33705690
Emerg Infect Dis. 2021 May;27(5):1343-1352
pubmed: 33900174
J Travel Med. 2021 Feb 23;28(2):
pubmed: 33283232
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32132196
One Health. 2021 Jul 10;13:100292
pubmed: 34295958
Eur J Epidemiol. 2021 Feb;36(2):179-196
pubmed: 33634345
Int J Infect Dis. 2021 Mar;104:139-149
pubmed: 33359061
Sultan Qaboos Univ Med J. 2021 May;21(2):e195-e202
pubmed: 34221466
Lancet Glob Health. 2021 Mar;9(3):e257-e266
pubmed: 33515512
N Engl J Med. 2020 May 14;382(20):e55
pubmed: 32212515
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Int J Infect Dis. 2020 Oct;99:466-472
pubmed: 32829052
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Int J Infect Dis. 2021 Aug;109:244-246
pubmed: 34260956
Int J Infect Dis. 2021 Jun;107:257-263
pubmed: 33930541
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293
Lancet Infect Dis. 2021 Apr;21(4):473-481
pubmed: 33338441
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
BMJ. 2020 Jul 7;370:m2728
pubmed: 32636189
Clin Biochem. 2021 Apr;90:15-22
pubmed: 33539808
Lancet Glob Health. 2020 Nov;8(11):e1390-e1398
pubmed: 32979314
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
PLoS Med. 2020 Oct 1;17(10):e1003358
pubmed: 33001967